Detalhe da pesquisa
1.
Uptake and effectiveness of newer biologic and targeted synthetic disease-modifying antirheumatic drugs in psoriatic arthritis: results from five Nordic biologics registries.
Ann Rheum Dis
; 82(6): 820-828, 2023 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-36813538
2.
Second and third TNF inhibitors in European patients with axial spondyloarthritis: Effectiveness and impact of the reason for switching.
Rheumatology (Oxford)
; 2023 Sep 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-37738257
3.
EULAR Points to Consider (PtC) for designing, analysing and reporting of studies with work participation as an outcome domain in patients with inflammatory arthritis.
Ann Rheum Dis
; 80(9): 1116-1123, 2021 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-33832966
4.
Response to: 'Correspondence on: irritable bowel syndrome symptoms in axial spondyloarthritis more common than among healthy controls: is it an overlooked comorbidity?' by Proft et al.
Ann Rheum Dis
; 81(1): e10, 2022 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31892532
5.
Irritable bowel syndrome symptoms in axial spondyloarthritis more common than among healthy controls: is it an overlooked comorbidity?
Ann Rheum Dis
; 79(1): 159-161, 2020 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31585930
6.
Differences and similarities between the EULAR/ASAS-EULAR and national recommendations for treatment of patients with psoriatic arthritis and axial spondyloarthritis across Europe.
Lancet Reg Health Eur
; 33: 100706, 2023 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-37601339